Cargando…

High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study

BACKGROUND: The current COVID-19 pandemic affects the entire world population and has serious health, economic and social consequences. Assessing the prevalence of COVID-19 through population-based serological surveys is essential to monitor the progression of the epidemic, especially in African cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Struck, Nicole S., Lorenz, Eva, Deschermeier, Christina, Eibach, Daniel, Kettenbeil, Jenny, Loag, Wibke, Brieger, Steven A., Ginsbach, Anna M., Obirikorang, Christian, Maiga-Ascofare, Oumou, Sarkodie, Yaw Adu, Boham, Eric Ebenezer Amprofi, Adu, Evans Asamoah, Asare, Gracelyn, Amoako-Adusei, Amos, Yawson, Alfred, Boakye, Alexander Owusu, Deke, James, Almoustapha, Nana Safi, Adu-Amoah, Louis, Duah, Ibrahim Kwaku, Ouedraogo, Thierry A., Boudo, Valentin, Rushton, Ben, Ehmen, Christa, Fusco, Daniela, Gunga, Leonard, Benke, Dominik, Höppner, Yannick, Rasolojaona, Zaraniaina Tahiry, Rasamoelina, Tahinamandranto, Rakotoarivelo, Rivo A., Rakotozandrindrainy, Raphael, Coulibaly, Boubacar, Sié, Ali, Awuah, Anthony Afum-Adjei, Amuasi, John H., Souares, Aurélia, May, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441841/
https://www.ncbi.nlm.nih.gov/pubmed/36064368
http://dx.doi.org/10.1186/s12889-022-13918-y
_version_ 1784782677551874048
author Struck, Nicole S.
Lorenz, Eva
Deschermeier, Christina
Eibach, Daniel
Kettenbeil, Jenny
Loag, Wibke
Brieger, Steven A.
Ginsbach, Anna M.
Obirikorang, Christian
Maiga-Ascofare, Oumou
Sarkodie, Yaw Adu
Boham, Eric Ebenezer Amprofi
Adu, Evans Asamoah
Asare, Gracelyn
Amoako-Adusei, Amos
Yawson, Alfred
Boakye, Alexander Owusu
Deke, James
Almoustapha, Nana Safi
Adu-Amoah, Louis
Duah, Ibrahim Kwaku
Ouedraogo, Thierry A.
Boudo, Valentin
Rushton, Ben
Ehmen, Christa
Fusco, Daniela
Gunga, Leonard
Benke, Dominik
Höppner, Yannick
Rasolojaona, Zaraniaina Tahiry
Rasamoelina, Tahinamandranto
Rakotoarivelo, Rivo A.
Rakotozandrindrainy, Raphael
Coulibaly, Boubacar
Sié, Ali
Awuah, Anthony Afum-Adjei
Amuasi, John H.
Souares, Aurélia
May, Jürgen
author_facet Struck, Nicole S.
Lorenz, Eva
Deschermeier, Christina
Eibach, Daniel
Kettenbeil, Jenny
Loag, Wibke
Brieger, Steven A.
Ginsbach, Anna M.
Obirikorang, Christian
Maiga-Ascofare, Oumou
Sarkodie, Yaw Adu
Boham, Eric Ebenezer Amprofi
Adu, Evans Asamoah
Asare, Gracelyn
Amoako-Adusei, Amos
Yawson, Alfred
Boakye, Alexander Owusu
Deke, James
Almoustapha, Nana Safi
Adu-Amoah, Louis
Duah, Ibrahim Kwaku
Ouedraogo, Thierry A.
Boudo, Valentin
Rushton, Ben
Ehmen, Christa
Fusco, Daniela
Gunga, Leonard
Benke, Dominik
Höppner, Yannick
Rasolojaona, Zaraniaina Tahiry
Rasamoelina, Tahinamandranto
Rakotoarivelo, Rivo A.
Rakotozandrindrainy, Raphael
Coulibaly, Boubacar
Sié, Ali
Awuah, Anthony Afum-Adjei
Amuasi, John H.
Souares, Aurélia
May, Jürgen
author_sort Struck, Nicole S.
collection PubMed
description BACKGROUND: The current COVID-19 pandemic affects the entire world population and has serious health, economic and social consequences. Assessing the prevalence of COVID-19 through population-based serological surveys is essential to monitor the progression of the epidemic, especially in African countries where the extent of SARS-CoV-2 spread remains unclear. METHODS: A two-stage cluster population-based SARS-CoV-2 seroprevalence survey was conducted in Bobo-Dioulasso and in Ouagadougou, Burkina Faso, Fianarantsoa, Madagascar and Kumasi, Ghana between February and June 2021. IgG seropositivity was determined in 2,163 households with a specificity improved SARS-CoV-2 Enzyme-linked Immunosorbent Assay. Population seroprevalence was evaluated using a Bayesian logistic regression model that accounted for test performance and age, sex and neighbourhood of the participants. RESULTS: Seroprevalence adjusted for test performance and population characteristics were 55.7% [95% Credible Interval (CrI) 49·0; 62·8] in Bobo-Dioulasso, 37·4% [95% CrI 31·3; 43·5] in Ouagadougou, 41·5% [95% CrI 36·5; 47·2] in Fianarantsoa, and 41·2% [95% CrI 34·5; 49·0] in Kumasi. Within the study population, less than 6% of participants performed a test for acute SARS-CoV-2 infection since the onset of the pandemic. CONCLUSIONS: High exposure to SARS-CoV-2 was found in the surveyed regions albeit below the herd immunity threshold and with a low rate of previous testing for acute infections. Despite the high seroprevalence in our study population, the duration of protection from naturally acquired immunity remains unclear and new virus variants continue to emerge. This highlights the importance of vaccine deployment and continued preventive measures to protect the population at risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-13918-y.
format Online
Article
Text
id pubmed-9441841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94418412022-09-06 High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study Struck, Nicole S. Lorenz, Eva Deschermeier, Christina Eibach, Daniel Kettenbeil, Jenny Loag, Wibke Brieger, Steven A. Ginsbach, Anna M. Obirikorang, Christian Maiga-Ascofare, Oumou Sarkodie, Yaw Adu Boham, Eric Ebenezer Amprofi Adu, Evans Asamoah Asare, Gracelyn Amoako-Adusei, Amos Yawson, Alfred Boakye, Alexander Owusu Deke, James Almoustapha, Nana Safi Adu-Amoah, Louis Duah, Ibrahim Kwaku Ouedraogo, Thierry A. Boudo, Valentin Rushton, Ben Ehmen, Christa Fusco, Daniela Gunga, Leonard Benke, Dominik Höppner, Yannick Rasolojaona, Zaraniaina Tahiry Rasamoelina, Tahinamandranto Rakotoarivelo, Rivo A. Rakotozandrindrainy, Raphael Coulibaly, Boubacar Sié, Ali Awuah, Anthony Afum-Adjei Amuasi, John H. Souares, Aurélia May, Jürgen BMC Public Health Research BACKGROUND: The current COVID-19 pandemic affects the entire world population and has serious health, economic and social consequences. Assessing the prevalence of COVID-19 through population-based serological surveys is essential to monitor the progression of the epidemic, especially in African countries where the extent of SARS-CoV-2 spread remains unclear. METHODS: A two-stage cluster population-based SARS-CoV-2 seroprevalence survey was conducted in Bobo-Dioulasso and in Ouagadougou, Burkina Faso, Fianarantsoa, Madagascar and Kumasi, Ghana between February and June 2021. IgG seropositivity was determined in 2,163 households with a specificity improved SARS-CoV-2 Enzyme-linked Immunosorbent Assay. Population seroprevalence was evaluated using a Bayesian logistic regression model that accounted for test performance and age, sex and neighbourhood of the participants. RESULTS: Seroprevalence adjusted for test performance and population characteristics were 55.7% [95% Credible Interval (CrI) 49·0; 62·8] in Bobo-Dioulasso, 37·4% [95% CrI 31·3; 43·5] in Ouagadougou, 41·5% [95% CrI 36·5; 47·2] in Fianarantsoa, and 41·2% [95% CrI 34·5; 49·0] in Kumasi. Within the study population, less than 6% of participants performed a test for acute SARS-CoV-2 infection since the onset of the pandemic. CONCLUSIONS: High exposure to SARS-CoV-2 was found in the surveyed regions albeit below the herd immunity threshold and with a low rate of previous testing for acute infections. Despite the high seroprevalence in our study population, the duration of protection from naturally acquired immunity remains unclear and new virus variants continue to emerge. This highlights the importance of vaccine deployment and continued preventive measures to protect the population at risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-13918-y. BioMed Central 2022-09-05 /pmc/articles/PMC9441841/ /pubmed/36064368 http://dx.doi.org/10.1186/s12889-022-13918-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Struck, Nicole S.
Lorenz, Eva
Deschermeier, Christina
Eibach, Daniel
Kettenbeil, Jenny
Loag, Wibke
Brieger, Steven A.
Ginsbach, Anna M.
Obirikorang, Christian
Maiga-Ascofare, Oumou
Sarkodie, Yaw Adu
Boham, Eric Ebenezer Amprofi
Adu, Evans Asamoah
Asare, Gracelyn
Amoako-Adusei, Amos
Yawson, Alfred
Boakye, Alexander Owusu
Deke, James
Almoustapha, Nana Safi
Adu-Amoah, Louis
Duah, Ibrahim Kwaku
Ouedraogo, Thierry A.
Boudo, Valentin
Rushton, Ben
Ehmen, Christa
Fusco, Daniela
Gunga, Leonard
Benke, Dominik
Höppner, Yannick
Rasolojaona, Zaraniaina Tahiry
Rasamoelina, Tahinamandranto
Rakotoarivelo, Rivo A.
Rakotozandrindrainy, Raphael
Coulibaly, Boubacar
Sié, Ali
Awuah, Anthony Afum-Adjei
Amuasi, John H.
Souares, Aurélia
May, Jürgen
High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study
title High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study
title_full High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study
title_fullStr High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study
title_full_unstemmed High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study
title_short High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study
title_sort high seroprevalence of sars-cov-2 in burkina-faso, ghana and madagascar in 2021: a population-based study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441841/
https://www.ncbi.nlm.nih.gov/pubmed/36064368
http://dx.doi.org/10.1186/s12889-022-13918-y
work_keys_str_mv AT strucknicoles highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT lorenzeva highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT deschermeierchristina highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT eibachdaniel highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT kettenbeiljenny highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT loagwibke highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT briegerstevena highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT ginsbachannam highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT obirikorangchristian highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT maigaascofareoumou highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT sarkodieyawadu highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT bohamericebenezeramprofi highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT aduevansasamoah highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT asaregracelyn highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT amoakoaduseiamos highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT yawsonalfred highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT boakyealexanderowusu highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT dekejames highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT almoustaphananasafi highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT aduamoahlouis highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT duahibrahimkwaku highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT ouedraogothierrya highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT boudovalentin highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT rushtonben highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT ehmenchrista highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT fuscodaniela highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT gungaleonard highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT benkedominik highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT hoppneryannick highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT rasolojaonazaraniainatahiry highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT rasamoelinatahinamandranto highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT rakotoarivelorivoa highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT rakotozandrindrainyraphael highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT coulibalyboubacar highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT sieali highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT awuahanthonyafumadjei highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT amuasijohnh highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT souaresaurelia highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy
AT mayjurgen highseroprevalenceofsarscov2inburkinafasoghanaandmadagascarin2021apopulationbasedstudy